


**Oxiris set has received Medical Device Regulation (MDR) certification.<sup>1</sup>**

It's the **only** blood purification filter set to effectively:<sup>2</sup>

- Remove **INFLAMMATORY MEDIATORS**
- Remove **ENDOTOXIN**
- Remove **UREMIC TOXINS and FLUIDS**

**SIMULTANEOUSLY.** [LEARN MORE](#)



**Baxter**

## Oxiris set receives Medical Device Regulation (MDR) Certification.<sup>1</sup>

Oxiris is the **ONLY** blood purification filter set to effectively remove inflammatory mediators, endotoxin, uremic toxins and fluids, **simultaneously.**<sup>2</sup>

Common acute conditions underpinned by a dysregulated inflammatory mediator response include sepsis<sup>3</sup> and possibly severe COVID-19.<sup>4</sup>

**Indications:**<sup>2</sup> The Oxiris set is indicated for use in critically ill patients with a body weight equal or greater than 30 kg (66 lb) for hemoperfusion and/or renal replacement modalities such as:

- Slow Continuous Ultrafiltration (SCUF)
- Continuous Veno-Venous Hemofiltration (CVVH)
- Continuous Veno-Venous Hemodialysis (CVVHD)
- Continuous Veno-Venous Hemodiafiltration (CVVHDF)

When used for hemoperfusion only, the SCUF mode shall be used with no fluid removal prescription, as the indication is to reduce elevated levels of inflammatory mediators, such as cytokines, and to reduce endotoxins.

If patients suffer from acute kidney injury and/or volume overload, the Oxiris set is indicated for continuous renal replacement therapies (CRRT), to perform fluid management and removal of uremic toxins. The removal of inflammatory mediators and endotoxins is performed simultaneously when indicated for CRRT.<sup>2</sup>

VERSATILITY, SIMPLIFIED.



CVVH, Continuous Veno-Venous Hemofiltration; CVVHD, Continuous Veno-Venous Hemodialysis; CVVHDF, Continuous Veno-Venous Hemodiafiltration; SCUF, Slow Continuous Ultrafiltration

The Oxiris set is a disposable, extracorporeal circuit for use with the PrismaFlex control unit or with the PrismaMax control unit (in countries where the PrismaMax system is cleared or registered).<sup>2</sup>

For safe and proper use, please refer to the appropriate Instructions for Use or Operator's Manual for use on the products mentioned herein.

**CE 0123**

1. <https://eur-lex.europa.eu>.

2. Baxter, Oxiris Instructions for Use, 2022.

3. Singer M, et al. *JAMA*, 2016; 315:801–810.

4. Nadim MK, et al. *Nat Rev Nephrol*, 2020; 16:747–764.



Privacy at Baxter | Copyright and Legal Disclaimers | Cookie Declarations  
Baxter, Oxiris, PrismaMax, and Prismaflex are trademarks of Baxter International Inc.

© 2022 Baxter. All rights reserved.

GBU-AT1-220946 v1.0 12/2022